AYAlqi Yutha

Alqi Yutha

*This is an algorithmically generated author record based on publicly available information.

Alqi Yutha has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Low molecular weight heparin is associated with better outcomes than unfractionated heparin for thromboprophylaxis in hospitalized COVID-19 patients: a meta-analysis

    by Mochamad Yusuf Alsagaff, Eka Prasetya Budi Mulia, Irma Maghfirah, Yusuf Azmi, Dita Aulia Rachmi, Alqi Yutha, Luqman Hakim Andira, Bambang Pujo Semedi

    This study aimed to compare the outcomes of administration of LMWH and UFH in hospitalized COVID-19 patients. We systematically searched several databases and included observational studies or clinical trials that compared the outcomes of administration of LMWH and UFH in hospitalized COVID-19 patients. A total of nine studies comprising 9637 patients were included. Metanalysis showed that LMWH administration was associated with a lower in-hospital mortality, and 28/30-day mortality compared with UFH administration ([RR 0.44; 95%CI 0.32–0.61; I2:87.9%] and [RR 0.45; 95%CI 0.24–0.86; I2:78.4%], respectively). Patient with LMWH had shorter duration of hospital and ICU length of stay compared with UFH ([WMD −2.20; 95%CI −3.01 to −1.40; I2:0%] and [WMD −1.41; 95%CI −2.20 to −0.63; I2:0%], respectively). The risk of ICU admission or mechanical ventilation was lower in patients who received LMWH than those who received UFH (RR 0.67; 95%CI 0.55–0.81; I2:67.3%). However, there was no difference in the incidence of bleeding with LMWH compared with UFH (RR 0.27; 95%CI 0.07–1.01; I2:64.6%). Our meta-analysis showed that administration of LMWH was associated with better outcomes compared with UFH in hospitalized COVID-19 patients. Prospective cohorts and RCTs are urgently needed in exploring the definitive effect of LMWH to provide direct high-certainty evidence. PROSPERO registration number: CRD42021271977